Target intelligence / Profile preview

Human cytomegalovirus tegument protein pp65 (UL83) (pp65 (UL83))

Target
pp65 (UL83)
Molecular classification
Other (viral tegument protein)
01

Overview

Human cytomegalovirus pp65 (UL83) is the most abundant tegument protein and a major constituent of extracellular virions; while not essential for replication in fibroblasts, it contributes to tegument assembly as an optional scaffold and influences incorporation of other viral proteins. It is a dominant target of humoral and cellular immunity, especially CD8+ cytotoxic T lymphocytes. pp65 modulates host innate antiviral defenses by inhibiting IRF3 activation and dampening IFN-responsive gene induction, and it can reduce NF-κB activation/nuclear translocation, thereby facilitating immune evasion. Because pp65-specific CTLs recognize pp65-derived peptides presented by MHC class I and kill infected cells through granule exocytosis (perforin/granzymes) and Fas–FasL pathways, pp65 is widely used as an antigen in HCMV vaccines and adoptive T-cell therapies rather than as a classical drug target.

Other names
HCMV pp65ppUL83UL83 proteinMajor tegument protein pp65
02

Mechanism of action

Vaccine/adoptive T-cell therapy context: pp65 serves as an immunodominant antigen to elicit or transfer pp65-specific CD8+ T cells that kill HCMV-infected cells via perforin/granzyme and Fas–FasL pathways.

03

Biological functions

Immune evasion (inhibits IRF3 activation; modulates IFN-like responses)Modulation of host antiviral signaling (affects NF-κB, IRF3)Tegument scaffolding/assembly (optional scaffold for tegument packaging)
04

Disease associations

Infection (Human cytomegalovirus pathogenesis; dominant CD8+ T-cell antigen)
05

Safety considerations

For pp65-targeted immunotherapies: risk of inadequate immune reconstitution or off-target immune effects is general to T-cell therapies; pp65 itself as a viral antigen poses low direct toxicity but immune manipulation can carry risks such as graft-versus-host disease or cytokine-related effects in adoptive cell therapy settings.
06

Interacting drugs

None established as direct small-molecule or biologic drugs binding pp65 for therapy. Antiviral drugs for HCMV (e.g., ganciclovir) target other viral proteins, not pp65. Vaccine candidates and adoptive T-cell therapies target pp65 as an antigen but are not “drug–target” interactions in the classic sense.
07

Biomarkers

pp65 antigenemia (pp65 in leukocytes) historically used to monitor HCMV replication/therapy response in transplant patients.Frequency/function of pp65-specific CD8+ T cells as an immune reconstitution marker after transplantation or vaccination.

Beyond the preview

Go deeper on Human cytomegalovirus tegument protein pp65 (UL83) (pp65 (UL83)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human cytomegalovirus tegument protein pp65 (UL83) (pp65 (UL83)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call